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Introduction: Recent studies described changes in platelet reactivity (PR) in days following transcath-
eter aortic valve implantation (TAVI).1 However, precise time course and duration of these changes 
have not been fully investigated. Aim of the study was to investigate PR changes during and after TAVI. 
Patients and Methods: Study included 40 consecutive patients with severe and symptomatic aortic 
stenosis undergoing transfemoral TAVI procedure. Patients’ clinical characteristics were collected 
from medical records. All patients who did not have chronic dual antiplatelet therapy received load-
ing dose of aspirin and clopidogrel (300 mg) one day before the procedure followed by their standard 
maintenance doses. PR was measured in seven time points: before start of procedure (T1), after hepa-
rin administration (T2), 10 minutes after valve implantation (T3), at the end of procedure (T4), and on 
3rd, 6th and 30th postoperative day (T5-7). PR was measured using impedance aggregometer in response 
to three platelet aggregation agonists using ASPI, ADP and TRAP test. 
Results: Mean patient age was 82.7 years with majority of patients being male 60% (N=25). All pa-
tients underwent successful transfemoral TAVI procedure using either self-expandable (N=25, 62.5 %) 
or balloon-expandable valve. Mean postimplantation gradient was 9.97±4.44 mmHg. More than mild 
paravalvular regurgitation persisted in 2 (5%) patients. Values of PR in each tested time point are pre-
sented in Table 1. There was no significant difference in PR between T1 and T2. After the valve implan-
tation significant reduction of PR in all 3 tests was observed. PR continued to decline on consecutive 
measurements, with lowest values reached on 3rd post-TAVI day (T5). On T6, value of ASPI test were not 
significantly different to the ones measured on T1, while values of ADP and TRAP test remained signif-
icantly lower. By 30th post-TAVI day PR values reached levels not significantly different compared to T1. 
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tABLe 1. Results of platelet reactivity test using ASpi, Adp and tRAp test in tested time points. 
T1 T2 T3 T4 T5 T6 T7 P
ASPI 22.97±23.01 19.17±19.61 10.36±11.60 10.23±11.38 9.71±10.68 15.28±17.32 20.97±21.26 < 0.001
ADP 40.46±23.68 33.11±20.45 24.15±14.07 22.18±12.63 14.95±8.59 27.81±17.96 33.11±23.60 < 0.001
TRAP 91.69±32.50 93.42±27.71 69.31±26.57 64.05±24.20 40.97±17.71 69.09±29.08 88.06±35.51 < 0.001
Values are presented in Units (U)
Conclusions: Presented results indicate that transfemoral TAVI induces transient decrease in PR re-
gardless of the platelet activation pathway. Significant reduction of PR is observed 10 minutes after 
valve implantation with continuous decrease until 3rd day post-TAVI after which it is gradually in-
creasing to pre-TAVI values.
